革兰氏阴性菌感染中抗生素体外协同作用的临床意义。
Clinical significance of in vitro synergism between antibiotics in gram-negative infections.
作者信息
Klastersky J, Cappel R, Daneau D
出版信息
Antimicrob Agents Chemother. 1972 Dec;2(6):470-5. doi: 10.1128/AAC.2.6.470.
Abstract
Five combinations of antibiotics (ampicillin/gentamicin, cephalothin/gentamicin, carbenicillin/gentamicin, polymyxin/carbenicillin, and carbenicillin/cephalothin) were investigated in vitro and in 148 severe infectious episodes caused by gram-negative bacilli in patients with disseminated cancer. The use of combinations that were synergistic in vitro against the offending microorganism (synergy was defined as occurring when the minimal inhibitory concentration of each of the drugs in the combination was one-quarter or less of the minimal inhibitory concentration of each drug alone) was associated with a significantly better response to antibacterial therapy (P < 0.01) than the use of combinations that were not synergistic against the causative agent.
摘要
对五种抗生素组合（氨苄西林/庆大霉素、头孢噻吩/庆大霉素、羧苄西林/庆大霉素、多粘菌素/羧苄西林以及羧苄西林/头孢噻吩）进行了体外研究，并在148例播散性癌症患者由革兰氏阴性杆菌引起的严重感染发作中进行了研究。对于体外对致病微生物具有协同作用的组合（协同作用定义为当组合中每种药物的最低抑菌浓度是每种药物单独使用时最低抑菌浓度的四分之一或更低时发生），与对致病因子无协同作用的组合相比，其抗菌治疗反应明显更好（P < 0.01）。
相似文献
1
Clinical significance of in vitro synergism between antibiotics in gram-negative infections.
Antimicrob Agents Chemother. 1972 Dec;2(6):470-5. doi: 10.1128/AAC.2.6.470.
2
Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.
JAMA. 1974 Jan 7;227(1):45-8. doi: 10.1001/jama.227.1.45.
3
Combinations of antibiotics for therapy of severe infections in cancer patients.
Eur J Cancer (1965). 1979;15 Suppl:3-13.
4
Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients.
Am J Med Sci. 1976 Mar-Apr;271(2):179-86. doi: 10.1097/00000441-197603000-00006.
5
Correlation of the results of antibiotic synergy and susceptibility testing in vitro with results in experimental mouse infections.
Crit Rev Microbiol. 1982;10(1):1-76. doi: 10.3109/10408418209113505.
6
Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.
Antimicrob Agents Chemother. 1977 Jun;11(6):956-64. doi: 10.1128/AAC.11.6.956.
7
In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics.
Antimicrob Agents Chemother. 1976 Apr;9(4):589-94. doi: 10.1128/AAC.9.4.589.
8
Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.
J Infect Dis. 1976 Nov;134 SUPPL:S433-40. doi: 10.1093/infdis/135.supplement_2.s433.
9
Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations.
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S559-71. doi: 10.1093/clinids/7.supplement_4.s559.
10
The use of synergistic combinations of antibiotics in patients with haematological diseases.
Clin Haematol. 1976 Jun;5(2):361-77.
引用本文的文献
1
Antibacterial, antifungal and antioxidant activities of whole plant chemical constituents of Rumex abyssinicus.
BMC Complement Med Ther. 2021 Jun 5;21(1):164. doi: 10.1186/s12906-021-03325-y.
2
When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.
Clin Lab Med. 2019 Sep;39(3):345-358. doi: 10.1016/j.cll.2019.04.002. Epub 2019 Jun 12.
3
When more is less: Emergent suppressive interactions in three-drug combinations.
BMC Microbiol. 2017 May 6;17(1):107. doi: 10.1186/s12866-017-1017-3.
4
Antimicrobial Activities of a Plethora of Medicinal Plant Extracts and Hydrolates against Human Pathogens and Their Potential to Reverse Antibiotic Resistance.
Int J Microbiol. 2015;2015:547156. doi: 10.1155/2015/547156. Epub 2015 May 27.
5
The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.
PLoS Pathog. 2013;9(4):e1003300. doi: 10.1371/journal.ppat.1003300. Epub 2013 Apr 4.
6
Combination therapy for treatment of infections with gram-negative bacteria.
Clin Microbiol Rev. 2012 Jul;25(3):450-70. doi: 10.1128/CMR.05041-11.
7
Synthesis and spectrum of the neoglycoside ACHN-490.
Antimicrob Agents Chemother. 2010 Nov;54(11):4636-42. doi: 10.1128/AAC.00572-10. Epub 2010 Aug 30.
8
Accelerated evolution of resistance in multidrug environments.
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13977-81. doi: 10.1073/pnas.0805965105. Epub 2008 Sep 8.
9
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Clin Transl Oncol. 2006 Dec;8(12):889-95. doi: 10.1007/s12094-006-0152-3.
10
Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
Antimicrob Agents Chemother. 2000 Dec;44(12):3264-71. doi: 10.1128/AAC.44.12.3264-3271.2000.
本文引用的文献
1
GENTAMICIN AND AMPICILLIN: SYNERGISM WITH OTHER ANTIBIOTICS.
Am J Med Sci. 1963 Dec;246:717-26. doi: 10.1097/00000441-196312000-00013.
2
Pneumonia caused by gram-negative bacilli in hospitalized patients presenting malignant disease.
Eur J Cancer (1965). 1971 Aug;7(4):329-36. doi: 10.1016/0014-2964(71)90076-4.
3
Antimicrobial activity of the carbenicillin-gentamicin combination against gram-negative bacilli.
Am J Med Sci. 1970 Dec;260(6):373-80. doi: 10.1097/00000441-197012000-00006.
4
Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia.
J Infect Dis. 1969 Jun;119(6):597-624. doi: 10.1093/infdis/119.6.597.
5
The use of combinations of antimicrobial drugs.
Annu Rev Pharmacol. 1968;8:151-70. doi: 10.1146/annurev.pa.08.040168.001055.
6
The importance of underlying disease in patients with gram-negative bacteremia.
Arch Intern Med. 1968 May;121(5):418-23.
7
In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa.
Appl Microbiol. 1969 Sep;18(3):469-73. doi: 10.1128/am.18.3.469-473.1969.
Zotero 插件